These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 25282395

  • 1. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G.
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A, Yigla M, Guralnik L, Hardak E, Solomonov A, Rozin AP, Toledano K, Dagan A, Bishara R, Markovits D, Nahir MA, Braun-Moscovici Y.
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [Abstract] [Full Text] [Related]

  • 5. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S.
    Arthritis Res Ther; 2016 Jun 02; 18(1):123. PubMed ID: 27255492
    [Abstract] [Full Text] [Related]

  • 6. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S.
    Arthritis Res Ther; 2016 Dec 30; 18(1):305. PubMed ID: 28038680
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S, Huscher D, Siegert E, Allanore Y, Czirják L, DelGaldo F, Denton CP, Distler O, Frerix M, Matucci-Cerinic M, Mueller-Ladner U, Tarner IH, Valentini G, Walker UA, Villiger PM, Riemekasten G, EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network.
    Arthritis Res Ther; 2018 Jan 30; 20(1):17. PubMed ID: 29382380
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C, Ngian GS, Elford K, Moore O, Stevens W, Nikpour M, Rabusa C, Proudman S, Roddy J, Zochling J, Hill C, Sturgess A, Tymms K, Youssef P, Sahhar J.
    Clin Exp Rheumatol; 2016 Jan 30; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
    Zheng JN, Yang QR, Zhu GQ, Pan L, Xia JX, Wang Q.
    Mod Rheumatol; 2020 Jul 30; 30(4):687-695. PubMed ID: 31269839
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
    Espinosa G, Simeón CP, Plasín MÁ, Xaubet A, Muñoz X, Fonollosa V, Cervera R, Vilardell M.
    Arch Bronconeumol; 2011 May 30; 47(5):239-45. PubMed ID: 21458128
    [Abstract] [Full Text] [Related]

  • 12. Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.
    Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG.
    Clin Exp Rheumatol; 2007 May 30; 25(5):734-9. PubMed ID: 18078622
    [Abstract] [Full Text] [Related]

  • 13. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
    Airò P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M, Grottolo A, Franceschini F, Zambruni A.
    Clin Exp Rheumatol; 2007 May 30; 25(2):293-6. PubMed ID: 17543156
    [Abstract] [Full Text] [Related]

  • 14. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT, Simons SO, Teesselink E, Knaapen-Hans HKA, van den Hoogen FHJ, Fransen J, Vonk MC.
    Clin Rheumatol; 2018 Oct 30; 37(10):2715-2722. PubMed ID: 29987427
    [Abstract] [Full Text] [Related]

  • 15. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.
    Ann N Y Acad Sci; 2007 Sep 30; 1110():271-84. PubMed ID: 17911442
    [Abstract] [Full Text] [Related]

  • 16. Effect of Sequential Intravenous Pulse Cyclophosphamide-Azathioprine in Systemic Sclerosis-Interstitial Lung Disease: An Open-Label Study.
    Kundu S, Paul S, Hariprasath K, Agarwal R, Ghosh S, Biswas D.
    Indian J Chest Dis Allied Sci; 2016 Sep 30; 58(1):7-10. PubMed ID: 28368564
    [Abstract] [Full Text] [Related]

  • 17. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
    Int J Rheum Dis; 2014 Nov 30; 17(8):923-8. PubMed ID: 24864029
    [Abstract] [Full Text] [Related]

  • 18. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
    Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.
    Arthritis Rheumatol; 2019 Dec 30; 71(12):2059-2067. PubMed ID: 31233287
    [Abstract] [Full Text] [Related]

  • 19. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S.
    J Dermatol; 2019 Nov 30; 46(11):1006-1013. PubMed ID: 31502326
    [Abstract] [Full Text] [Related]

  • 20. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.
    Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S, Andalib E.
    Rheumatol Int; 2014 Dec 30; 34(12):1691-9. PubMed ID: 24801572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.